Want to see HROW full AI Analyst Report?
HROW Stock Chart & Stats
$38.45
-$0.70(-1.82%)
At close: 4:00 PM EDT
$38.45
-$0.70(-1.82%)
Day’s Range― - ―
52-Week Range$28.54 - $54.85
Previous CloseN/A
Volume279.61K
Average Volume (3M)705.12K
Market Cap
$1.48B
Enterprise Value$1.80K
Total Cash (Recent Filing)$83.89M
Total Debt (Recent Filing)$300.74M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Nov 16, 2026EPS Estimate
0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding37,487,850
10 Day Avg. Volume609,551
30 Day Avg. Volume705,119
Financial Highlights & Ratios
PEG Ratio4.90
Price to Book (P/B)34.35
Price to Sales (P/S)6.61
P/FCF Ratio42.12
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$66.67Price Target Upside73.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.23
Revenue Forecast (FY)$348.48M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue GrowthSustained top-line growth with very high gross margins (low-70% TTM) indicates strong product economics and pricing power in ophthalmics. Durable margins provide room to invest in sales/marketing and R&D while enabling operating leverage as commercial scale and reimbursement recovery persist.
Improved Cash GenerationA turnaround to positive operating and free cash flow is a structural improvement in liquidity and funding capacity. Consistent cash generation reduces near-term refinancing need, supports the $30M TYRVAYA payment, and provides a base to deleverage and fund commercial expansion without immediate equity dilution.
Portfolio Expansion & Market AccessAcquiring TYRVAYA and launching BYOOVIZ materially broaden Harrow’s ophthalmic portfolio and treatment options. Combined with top‑3 PBM coverage for VEVYE and expanding prescriber reach, this structurally increases addressable market, cross‑sell potential, and long‑term revenue diversification across dry eye and retina franchises.
Bears Say
Elevated LeverageDebt-funded growth and a materially reduced equity cushion leave the balance sheet vulnerable to revenue or margin setbacks. Higher leverage increases refinancing, interest, and covenant risks, limiting flexibility for opportunistic investments or cushioning against commercial execution delays over the next several quarters.
Widening Net LossesDespite strong gross margins, net losses have widened and operating profit remains near break‑even, reflecting elevated SG&A and integration costs. Persistent negative earnings constrain retained capital, raise dilution risk if equity raises are needed, and demand sustained operating leverage to reach consistent profitability.
Execution & Integration RiskMeeting full‑year guidance requires a material H2 revenue acceleration, plus integration of TYRVAYA and ~+$20M annualized SG&A. This concentrated execution risk—relying on rep productivity, channel normalization, and successful integration—could strain margins and cash if uptake or timing disappoints over the next 2–6 months.
Harrow Health News
HROW FAQ
What was Harrow Health Inc’s price range in the past 12 months?
Harrow Health Inc lowest stock price was $28.54 and its highest was $54.85 in the past 12 months.
What is Harrow Health Inc’s market cap?
Harrow Health Inc’s market cap is $1.48B.
When is Harrow Health Inc’s upcoming earnings report date?
Harrow Health Inc’s upcoming earnings report date is Nov 16, 2026 which is in 94 days.
How were Harrow Health Inc’s earnings last quarter?
Harrow Health Inc released its earnings results on Aug 10, 2026. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.179 by -$0.281.
Is Harrow Health Inc overvalued?
According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued.
Does Harrow Health Inc pay dividends?
Harrow Health Inc does not currently pay dividends.
What is Harrow Health Inc’s EPS estimate?
Harrow Health Inc’s EPS estimate is 0.25.
How many shares outstanding does Harrow Health Inc have?
Harrow Health Inc has 37,487,850 shares outstanding.
What happened to Harrow Health Inc’s price movement after its last earnings report?
Harrow Health Inc reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.179. Following the earnings report the stock price went down -3.145%.
Which hedge fund is a major shareholder of Harrow Health Inc?
Currently, no hedge funds are holding shares in HROW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harrow Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.67 (73.39% Upside)
$66.67 (73.39% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 682.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $468.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 10.3%
Last 30 Days ▼ 10.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.21%
Trailing 12-Months
Company Description
Harrow Health Inc
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
HROW Company Deck
HROW Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum across multiple franchises (VEVYE, IHEEZO, TRIESENCE), record unit demand, successful market-access wins, pipeline progress (pre-NDA for MELT-300), and reiterated full-year guidance—supporting an optimistic outlook. Offsetting risks include a weaker-than-expected first half, negative adjusted EBITDA in the quarter, channel inventory/revenue timing effects, the need for a sizable second-half revenue ramp to meet guidance, and near-term SG&A and acquisition-related cash outflows. On balance, management presented credible operational and commercial drivers to achieve the required second-half acceleration, but execution and integration risks remain material.View all HROW earnings summariesHROW Stock 12 Month Forecast
Average Price Target
$66.67
▲(73.39% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
20.11% Insiders
9.72% Mutual Funds
4.00% Other Institutional Investors
53.44% Public Companies and Individual Investors